

# Q1-2022 Pharmaceutical Services Update

## Market Update

The first quarter of 2022 was another exciting quarter for deal activity within the broader outsourced pharma services space. The start of the year has observed many diverse transactions across several sub-verticals of pharma services, including amongst CDMOs, clinical research sites / organizations, consulting and other human capital-based companies, and software / tech-enabled companies. Provident closed two site transactions in 2021 and is currently working on a number of other pharma services mandates. Provident also expects this fragmented space to mirror 2021's consolidation activity as investors and strategic buyers still remain well capitalized.

## Select Transactions:

Month	Acquirer	Target	Target Focus	Target Geography
March	IMA Clinical Research	Amici Clinical Research	Clinical Research	United States (New Jersey)
March	Arsenal Capital Partners	Innovative Edge	Consulting	United Kingdom (England)
February	Recipharm	Vibalogs	CDMO	Europe (Germany)
February	Ergomed	Adamas Consulting	Consulting	United Kingdom (England)
February	CGE Partners	Datapharm	Software	United Kingdom (England)
February	Crane Street Capital	Paradigm Clinical Research Centers	Clinical Research	United States (California)
January	IntegriChain	Blue Fin Group	Consulting	United States (New York)
January	CenExel Clinical Research	Rocky Mountain Movement Disorders Center	Clinical Research	United States (Colorado)
January	CenExel Clinical Research	California Neuroscience Research	Clinical Research	United States (California)
January	CATO SMS	Pharm-Olam	CRO	United States (Texas)
January	TriNetX	Advera Health Analytics	Pharma-covigilance	United States (California)

## Provident Industry Coverage Team

**Michael Patton**  
*Managing Director*  
 mpatton@providenthp.com  
 (617) 226-4205

**Kevin McDermott**  
*Associate*  
 kmcdermott@providenthp.com  
 (310) 919-4011

**Daniel O'Brien**  
*Analyst*  
 dobrien@providenthp.com  
 (617) 226-4292